CAS 910463-68-2

General Information

Semaglutide (sold under brand names Ozempic® (Injection) and Rybelsus® (Oral) is a recombinant DNA produced polypeptide analogue of human glucagon-like peptide-1 (GLP-1) which is used in the therapy of type 2 diabetes.

Semaglutide is specifically indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

About the API

Trade name(s) Ozempic
Molecular Formula C187H291N45O59
Molecular Weight 4114 g/mol
Physical properties Small Molecule
Therapeutic category Diabetes
Available formulations Injectables